Current Report Filing (8-k)
October 23 2017 - 8:16AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 2, 2017
IMMUDYNE,
INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
333-184487
|
|
76-0238453
|
(State or other Jurisdiction
of Incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification No.)
|
1460
Broadway
New
York, NY
|
|
10036
|
(Address of Principal
Executive Offices)
|
|
(Zip Code)
|
Registrant’s
telephone number, including area code:
(914) 244-1777
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers’ Compensatory
Arrangements of Certain Officers.
On
October 2, 2017, Robert Kalkstein was appointed as the Chief Financial Officer of Immudyne, Inc. (the “Company”).
Mr. Kalkstein has years of experience in audit, banking and as chief financial officer of several emerging growth companies. Previously,
Mr. Kalkstein held positions at Peerless System Corp., Jefferies & Co. and PricewaterhouseCoopers. He has more than 10 years
of experience in the areas of accounting, finance, SEC compliance and operations. Mr. Kalkstein is a CPA and received a Bachelor
of Engineering in Biomedical Engineering and a Masters of Engineering in Engineering Management at Stevens Institute of Technology
in Hoboken, NJ.
Mr.
Kalkstein entered into a consulting agreement with the Company, which provides, among other things, for a fee of $2,750 per month
through December 2017, $5,000 per month between January 2018 and March 2018 and $7,500 per month between April 2018 and September
2018. Additionally, Mr. Kalkstein was granted an option to purchase 500,000 shares of the Company’s common stock at $0.40
per share, subject to the approval of the board of directors of the Company and certain vesting requirements set forth in the
consulting agreement. The foregoing description of Mr. Kalkstein’s consulting agreement is qualified by reference to the
full text of such agreement, which is filed herewith as Exhibit 10.1.
There
are no family relationships between Mr. Kalkstein and any director or other executive officer of the Company nor are there any
transactions between Mr. Kalkstein or any member of his immediate family and the Company or any of its subsidiaries that would
be reportable as a related party transaction under the rules of the United States Securities and Exchange Commission. Further,
there is no arrangement or understanding between Mr. Kalkstein and any other persons or entities pursuant to which Mr. Kalkstein
was appointed as an executive officer of the Company.
Item
9.01. Financial Statements and Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
IMMUDYNE
INC.
|
|
(Registrant)
|
|
|
Date: October 23, 2017
|
By:
|
/s/
Mark McLaughlin
|
|
Name:
|
Mark McLaughlin
|
|
Title:
|
Chief Executive Officer
|
3